• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD must make a difficult decision about whether to continue or stop taking ADHD medication during pregnancy and breast-feeding. There are few data on how exposure to ADHD for a long time could affect a foetus.

A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus don't develop neurological conditions like impaired vision or hearing seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality studies.

Risk/Benefit Analysis

Women who are expecting and taking ADHD medication should consider the benefits of taking it against the possible risks to the fetus. Physicians don't have the data to provide clear recommendations, but can provide information about risks and benefits to assist pregnant women to make an informed decision.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during their early pregnancy were not at greater risk of fetal malformations or structural birth defects. The researchers used a large population-based study of case-control to assess the risk of major structural birth defects in babies born to mothers who had taken stimulants in the early stages of pregnancy and those who had not. Pediatric cardiologists, clinical geneticists and other experts examined the cases to confirm that the classification was correct and to minimize any bias.

The study conducted by the researchers was not without its limitations. Most important, they were unable to distinguish the effects of the medication from the disorder that is underlying. That limitation makes it difficult to determine whether the small differences observed in the exposed groups are due to medication use or the confounding effect of comorbidities. In addition the researchers did not examine long-term offspring outcomes.

The study did reveal that infants whose mothers had taken ADHD medications during pregnancy were at a higher risk of being admitted to the neonatal intensive care unit (NICU) than those whose mothers had not taken any medication or had taken off their medication prior to or during pregnancy. This increase was due to central nervous system disorders, and the increased risk of admission was not found to be influenced by the stimulant medications were taken during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having to have a caesarean section or the baby was not scoring well on the Apgar scale (less than 7). These risks did not seem to be influenced by the type of medication that was used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during the early stages of pregnancy may be offset by the greater benefits for both mother and child from continued treatment for the woman's condition. Physicians should discuss the issue with their patients and, where possible, assist them in developing strategies to improve their coping abilities that can lessen the negative impact of her condition on her daily life and relationships.

Interactions with medication given for adhd

Doctors are increasingly confronted with the dilemma of whether to continue treatment or stop as more women are diagnosed with ADHD. Often, these decisions are made in the absence of clear and authoritative evidence regardless, so doctors must weigh what they know about their experiences, the experiences of other doctors, and what the research suggests on the subject, along with their own best judgment for each individual patient.

The issue of potential risks to infants is particularly tricky. Many studies on this issue are based on observational evidence instead of controlled research and their conclusions are often contradictory. Most studies focus on live-births, which could underestimate the severity of teratogenic effects that can lead to terminations or abortions of pregnancy. The study presented in the journal club addresses these limitations by analyzing both the data from deceased and live births.

Conclusion Some studies have shown an association between ADHD medications and certain birth defects, other studies have not established a link. The majority of studies show that there is a neutral, or somewhat negative, impact. In every case it is imperative to conduct a thorough analysis of the potential risks and benefits is required.

For women suffering from ADHD and ADD, the decision to stop taking medication for adhd and anxiety in adults is difficult if not impossible. In fact, in an article recently published in Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of isolation, and family conflict for these patients. In addition, a decrease in medication can interfere with the ability to perform jobs and drive safely which are essential aspects of daily life for many people with ADHD.

She suggests women who are unsure about whether to keep or discontinue medication due to their pregnancy should consider the possibility of educating friends, family members and colleagues on the condition, its effects on daily functioning, and the advantages of continuing the current treatment plan. It will also help a woman feel confident about her decision. It is important to note that certain drugs can be absorbed through the placenta so if a woman decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware that traces of the drug can be passed on to the baby.

Birth Defects and adhd medication uk Elvanse Risk of

As the use of adhd medication uk elvanse - simply click the following site, drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases, so do concerns over the impact that these drugs could have on foetuses. A study that was published in the journal Molecular Psychiatry adds to the body of information on this topic. Researchers used two massive datasets to analyze more than 4.3 million pregnancies and determine if stimulant medication use caused birth defects. While the overall risk is low, the researchers discovered that the first-trimester exposure to ADHD medications was linked to a slightly higher rate of certain heart defects such as ventriculoseptal defect (VSD).

The researchers of the study could not discover any link between the use of early medications and congenital anomalies like facial deformities or club feet. The results are in line with previous studies that showed the existence of a slight, but significant increase in the number of cardiac malformations among women who began taking ADHD medication prior to the time of pregnancy. This risk increased during the latter half of pregnancy when a large number of women began to stop taking their medication.

Women who were taking ADHD medication in the first trimester were more likely require a caesarean delivery and also have a low Apgar after delivery and had a baby that required help breathing after birth. The researchers of the study could not eliminate bias due to selection because they restricted the study to women with no other medical conditions that could have contributed to the findings.

The researchers hope their research will aid in the clinical decisions of physicians who see pregnant women. The researchers advise that while discussing the risks and benefits are important, the decision about whether to continue or stop medication should be made based on the severity of each woman's ADHD symptoms and the needs of the woman.

The authors also advise that, while stopping the medication for inattentive adhd is an option, it isn't a recommended practice because of the high prevalence of depression and other mental health problems among women who are pregnant or who are recently postpartum. Further, the research suggests that women who decide to stop taking their medications are more likely to experience a difficult time adjusting to life without them following the baby's arrival.

Nursing

It can be overwhelming to become a mother. Women with ADHD are often faced with a number of difficulties when they must deal with their symptoms, go to doctor appointments and prepare for the birth of their child and adjust to a new routine. Many women decide to continue taking their ADHD medication during pregnancy.

The majority of stimulant medicines are absorbed by breast milk in small amounts, so the risk to infant who is breastfeeding is low. The amount of exposure to medications can vary depending upon the dosage, frequency of administration and the time of day. In addition, individual medications enter the infant's system differently through the gastrointestinal tract and breast milk, and the effect of this on a newborn isn't yet fully known.

Some physicians may discontinue stimulant medications during a woman's pregnancy due to the lack of research. It's a difficult choice for the mother, who must weigh the benefits of her medication against the potential risks to the fetus. As long as there is no more information, doctors should ask all pregnant patients about their history of adhd medication names for adults and if they plan or are taking to take medication during the perinatal time.

Numerous studies have demonstrated that women can continue taking their ADHD medication without risk during pregnancy and breast-feeding. As a result, an increasing number of patients opt to do this and in consultation with their physician, they have found that the benefits of continuing their current medication far outweigh any risks.

It is crucial for women suffering from ADHD who are contemplating breastfeeding to seek out a specialist psychiatrist's guidance prior to becoming pregnant. They should discuss their medication with their doctor as well as the pros and cons for continuing treatment. This includes non-pharmacological methods. Psychoeducation is also needed to help pregnant women with ADHD understand the symptoms and the underlying disorder. They should also learn about treatment options and reinforce the coping mechanisms. This should be a multidisciplinary approach with the GPs, obstetricians and psychiatry. Counselling for pregnancy should include the discussion of a treatment plan for both the mother as well as the child, and monitoring for signs of deterioration, and when necessary, making adjustments to the medication regimen.